Back to Search Start Over

Enantioseparation of phenothiazines through capillary electrophoresis with solid phase extraction and polymer based stacking.

Authors :
Tseng WB
Hsieh MM
Chiu TC
Yu PL
Chen SH
Source :
Journal of food and drug analysis [J Food Drug Anal] 2018 Jul; Vol. 26 (3), pp. 1171-1179. Date of Electronic Publication: 2018 Jan 12.
Publication Year :
2018

Abstract

This study developed a sensitive method involving capillary electrophoresis (CE) coupled with ultraviolet absorption for the simultaneous separation of chiral phenothiazine drugs at nanomolar concentration levels. The method consists of hydroxypropyl-γ-cyclodextrin (Hp-γ-CD) as a chiral selector and poly (diallyldimethylammonium chloride) (PDDAC)-based CE. Five pairs of d,l-phenothiazines were baseline separated using a background electrolyte containing 0.9% PDDAC, 5 mM Hp-γ-CD, and 100 mM tris(hydroxymethyl)aminomethane (Tris)-formate (pH 3.0). The five pairs were successfully stacked on the basis of the difference in viscosity between the PDDAC-containing background electrolyte and the sample solution, with almost no loss of resolution. The combination of a solid-phase extraction and PDDAC-mediated CE can efficiently improve the sensitivity of the phenothiazine enantiomers. Under optimal conditions, calibration graphs displayed the linear range between 6 and 1500 nM, with relative standard deviation values lower than 3.5% (n = 5). Detection limit ranged from 2.1 to 6.3 nM for target analytes, and 607- to 1555-fold enhancement was achieved. The practicality of using the proposed method to determine five pairs of d,l-phenothiazines in urine is also validated, in which recoveries between recoveries of all phenothiazines from urine ranged from 89% to 101%.<br /> (Copyright © 2018. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
2224-6614
Volume :
26
Issue :
3
Database :
MEDLINE
Journal :
Journal of food and drug analysis
Publication Type :
Academic Journal
Accession number :
29976409
Full Text :
https://doi.org/10.1016/j.jfda.2017.12.002